Copyright Reports & Markets. All rights reserved.

Global Antidiabetic Glucagon-like Peptide 1 Agonists Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Exenatied
    • 1.3.3 Liraglutide
    • 1.3.4 Lixisenatide
    • 1.3.5 Albiglutide
    • 1.3.6 Dulaglutide
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospital
    • 1.4.3 Pharmacy
  • 1.5 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size & Forecast
    • 1.5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020 & 2024 & 2031)
    • 1.5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity (2020-2031)
    • 1.5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price (2020-2031)

2 Manufacturers Profiles

  • 2.1 Novo Nordisk
    • 2.1.1 Novo Nordisk Details
    • 2.1.2 Novo Nordisk Major Business
    • 2.1.3 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.1.4 Novo Nordisk Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Novo Nordisk Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.2.4 AstraZeneca Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 AstraZeneca Recent Developments/Updates
  • 2.3 Eli Lily
    • 2.3.1 Eli Lily Details
    • 2.3.2 Eli Lily Major Business
    • 2.3.3 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.3.4 Eli Lily Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Eli Lily Recent Developments/Updates
  • 2.4 GSK
    • 2.4.1 GSK Details
    • 2.4.2 GSK Major Business
    • 2.4.3 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.4.4 GSK Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 GSK Recent Developments/Updates
  • 2.5 Sanofi
    • 2.5.1 Sanofi Details
    • 2.5.2 Sanofi Major Business
    • 2.5.3 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.5.4 Sanofi Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Sanofi Recent Developments/Updates
  • 2.6 Bristol-Myers Squibb
    • 2.6.1 Bristol-Myers Squibb Details
    • 2.6.2 Bristol-Myers Squibb Major Business
    • 2.6.3 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.6.4 Bristol-Myers Squibb Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 Bristol-Myers Squibb Recent Developments/Updates
  • 2.7 Abbott Laboratories
    • 2.7.1 Abbott Laboratories Details
    • 2.7.2 Abbott Laboratories Major Business
    • 2.7.3 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Product and Services
    • 2.7.4 Abbott Laboratories Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Abbott Laboratories Recent Developments/Updates

3 Competitive Environment: Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer

  • 3.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Manufacturer (2020-2025)
  • 3.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Revenue by Manufacturer (2020-2025)
  • 3.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Manufacturer (2020-2025)
  • 3.4 Market Share Analysis (2024)
    • 3.4.1 Producer Shipments of Antidiabetic Glucagon-like Peptide 1 Agonists by Manufacturer Revenue ($MM) and Market Share (%): 2024
    • 3.4.2 Top 3 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2024
    • 3.4.3 Top 6 Antidiabetic Glucagon-like Peptide 1 Agonists Manufacturer Market Share in 2024
  • 3.5 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Overall Company Footprint Analysis
    • 3.5.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Region Footprint
    • 3.5.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Type Footprint
    • 3.5.3 Antidiabetic Glucagon-like Peptide 1 Agonists Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
    • 4.1.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2020-2031)
    • 4.1.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2020-2031)
    • 4.1.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Region (2020-2031)
  • 4.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020-2031)
  • 4.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020-2031)
  • 4.4 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020-2031)
  • 4.5 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020-2031)
  • 4.6 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value (2020-2031)

5 Market Segment by Type

  • 5.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 5.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Type (2020-2031)
  • 5.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Type (2020-2031)

6 Market Segment by Application

  • 6.1 Global Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 6.2 Global Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Application (2020-2031)
  • 6.3 Global Antidiabetic Glucagon-like Peptide 1 Agonists Average Price by Application (2020-2031)

7 North America

  • 7.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 7.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 7.3 North America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
    • 7.3.1 North America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2020-2031)
    • 7.3.2 North America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2020-2031)
    • 7.3.3 United States Market Size and Forecast (2020-2031)
    • 7.3.4 Canada Market Size and Forecast (2020-2031)
    • 7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe

  • 8.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 8.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 8.3 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
    • 8.3.1 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2020-2031)
    • 8.3.2 Europe Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2020-2031)
    • 8.3.3 Germany Market Size and Forecast (2020-2031)
    • 8.3.4 France Market Size and Forecast (2020-2031)
    • 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
    • 8.3.6 Russia Market Size and Forecast (2020-2031)
    • 8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific

  • 9.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 9.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 9.3 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Region
    • 9.3.1 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Region (2020-2031)
    • 9.3.2 Asia-Pacific Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Region (2020-2031)
    • 9.3.3 China Market Size and Forecast (2020-2031)
    • 9.3.4 Japan Market Size and Forecast (2020-2031)
    • 9.3.5 South Korea Market Size and Forecast (2020-2031)
    • 9.3.6 India Market Size and Forecast (2020-2031)
    • 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
    • 9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America

  • 10.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 10.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 10.3 South America Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
    • 10.3.1 South America Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2020-2031)
    • 10.3.2 South America Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2020-2031)
    • 10.3.3 Brazil Market Size and Forecast (2020-2031)
    • 10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa

  • 11.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Type (2020-2031)
  • 11.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Application (2020-2031)
  • 11.3 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Market Size by Country
    • 11.3.1 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Sales Quantity by Country (2020-2031)
    • 11.3.2 Middle East & Africa Antidiabetic Glucagon-like Peptide 1 Agonists Consumption Value by Country (2020-2031)
    • 11.3.3 Turkey Market Size and Forecast (2020-2031)
    • 11.3.4 Egypt Market Size and Forecast (2020-2031)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
    • 11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics

  • 12.1 Antidiabetic Glucagon-like Peptide 1 Agonists Market Drivers
  • 12.2 Antidiabetic Glucagon-like Peptide 1 Agonists Market Restraints
  • 12.3 Antidiabetic Glucagon-like Peptide 1 Agonists Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Antidiabetic Glucagon-like Peptide 1 Agonists and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Antidiabetic Glucagon-like Peptide 1 Agonists
  • 13.3 Antidiabetic Glucagon-like Peptide 1 Agonists Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Distributors
  • 14.3 Antidiabetic Glucagon-like Peptide 1 Agonists Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Antidiabetic Glucagon-like Peptide 1 Agonists market size was valued at US$ 6103 million in 2024 and is forecast to a readjusted size of USD 8113 million by 2031 with a CAGR of 4.2% during review period.
    Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
    The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
    This report is a detailed and comprehensive analysis for global Antidiabetic Glucagon-like Peptide 1 Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Antidiabetic Glucagon-like Peptide 1 Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
    Global Antidiabetic Glucagon-like Peptide 1 Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Antidiabetic Glucagon-like Peptide 1 Agonists
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Antidiabetic Glucagon-like Peptide 1 Agonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Antidiabetic Glucagon-like Peptide 1 Agonists market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Exenatied
    Liraglutide
    Lixisenatide
    Albiglutide
    Dulaglutide
    Market segment by Application
    Hospital
    Pharmacy
    Major players covered
    Novo Nordisk
    AstraZeneca
    Eli Lily
    GSK
    Sanofi
    Bristol-Myers Squibb
    Abbott Laboratories
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Antidiabetic Glucagon-like Peptide 1 Agonists product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Antidiabetic Glucagon-like Peptide 1 Agonists, with price, sales quantity, revenue, and global market share of Antidiabetic Glucagon-like Peptide 1 Agonists from 2020 to 2025.
    Chapter 3, the Antidiabetic Glucagon-like Peptide 1 Agonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Antidiabetic Glucagon-like Peptide 1 Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Antidiabetic Glucagon-like Peptide 1 Agonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Antidiabetic Glucagon-like Peptide 1 Agonists.
    Chapter 14 and 15, to describe Antidiabetic Glucagon-like Peptide 1 Agonists sales channel, distributors, customers, research findings and conclusion.

    Buy now